Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Semaglutide
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
China's First Biosimilar Ozempic Drug Applies for Approval
Details : Jiyoutai (semaglutide) is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Brand Name : Jiyoutai
Molecule Type : Peptide
Upfront Cash : Not Applicable
April 03, 2024
Lead Product(s) : Semaglutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?